Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.
about
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patientsExtracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patientsPhysical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patientsNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group ReportPreliminary Results on the Feasibility of Using ARFI/SWEI to Assess Cutaneous Sclerotic Diseases.Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.Nutritional status and hyperglycemia in the peritransplant period: a review of associations with parenteral nutrition and clinical outcomesCombining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effectsCurrent issues in chronic graft-versus-host disease.Graft-versus-host disease: state of the science.Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host diseaseHow we treat chronic graft-versus-host disease.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Clinical impact of H-Y alloimmunityTreatment of chronic graft-versus-host disease: Past, present and future.Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium studyProlonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseReduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.Proteomic analysis of saliva from patients with oral chronic graft-versus-host diseaseOutcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.Evaluation of prognostic factors among patients with chronic graft-versus-host disease.Brazilian workshop model to train investigators in chronic graft-versus-host disease clinical trials according to the 2005-2006 National Institutes of Health recommendations.Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host diseaseAllogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.
P2860
Q24187102-50BC564D-E835-4DA7-9A54-7CC964DBB294Q24200272-B4336782-5A5B-4752-845F-040E1E42DE1BQ26787230-F44039F6-A6B7-40F6-AFCA-60CAEA2597DEQ26827651-BE6D6697-46E2-4802-879E-B8F625E46B93Q30371343-3154C0AE-7AF4-4112-BE32-9AF87B8F3FACQ30408294-A1CE7E0E-6B9C-4E79-A5CB-56766C9A3239Q33756719-EE7705D5-7513-459F-8D4F-96A273746387Q33758951-116BA624-AFF9-43BA-AD5F-952B0A7E7FEBQ33809599-B3FBD368-DD7E-4C1D-8355-04335AB30758Q33905411-07361B95-570D-42E1-A367-6070A77D0003Q33917187-257C5021-C80B-46AF-B9AE-42EF04A50950Q33977923-6E43B2E8-EF0A-4D3E-81B9-324EB8329CE1Q34272547-544C3DB1-8726-40A7-B3B3-DBF77BE855FDQ35004923-0C63E9C6-9B87-44BF-B00D-4A2414287A2FQ35085226-BA6A5441-E196-4B3B-A9A9-831A3C9A646EQ35140097-1756A374-7512-4C76-A170-47509DFFA39CQ35235186-FC07AB10-85FD-4BEF-98F8-A05CA61BD7E9Q35524687-05278ACF-A802-47D6-8F4C-54A35EB62126Q35692054-D7E88BAB-FB27-4815-BC82-3010650F8B3DQ35794478-257261C4-DF4B-4912-AC19-531374195AC3Q35800856-4812555D-67C4-4A6F-BA39-762A663FA048Q35953410-244EB040-FC38-407F-B64F-FBD25FD6FE01Q36004178-482D2F8B-7CE7-4254-95FE-20DA21551981Q36040293-7E68E774-FBEB-4CF4-9A6B-DF331BFCB546Q36133013-33EB1AF0-0848-4CB8-BC99-D4F8CDEBAA8AQ36153664-2AF4CBC7-2459-487D-AFE1-8F6971589970Q36252702-2D37ECF8-D233-483B-A05D-771245948B20Q36530726-29CE7931-0057-48B7-B658-7B122F4EC605Q36662042-DB7A5ACD-B0A4-4F48-B5CE-E20BFE588D84Q36709850-7EE09412-273D-43D9-9AE0-7FD9C8DBB3B5Q36747224-719E84B3-148E-4AB9-A99C-2F0E952CF2CAQ36813127-A1AB6BDF-5EAE-4FC8-AAAC-24189FA1BB9BQ36876981-F01355FC-BE1D-4DB6-843F-16CAACCFBCB8Q36905580-73F13D8B-1BFB-4616-92FE-F03D24C47C20Q36928725-A9E00C01-D958-446B-B122-E60ECC4F9F97Q36940174-82C70CB2-75A9-49F6-972D-6891D5BDB0CBQ37104254-4C0DC93F-38F4-4830-9A9F-ECA9A4D7B803Q37104281-0ADFFDE9-F908-4599-ACEA-A4E7E3E30FE0Q37113099-C5BA5192-A812-47B2-8491-9610501DD334Q37212916-746B6725-ED03-4D30-9FF8-666F822122D2
P2860
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.
@ast
Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.
@en
type
label
Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.
@ast
Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.
@en
prefLabel
Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.
@ast
Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.
@en
P2093
P2860
P1433
P1476
Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.
@en
P2093
Corey Cutler
Daniel J Weisdorf
David Jacobsohn
Georgia B Vogelsang
Jeanne Palmer
Joseph Pidala
Madan Jagasia
Mary E D Flowers
Mukta Arora
Paul J Martin
P2860
P304
P356
10.1182/BLOOD-2011-03-344390
P407
P577
2011-07-26T00:00:00Z